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ABSTRACT 
Following a request from the European Commission, the Panel on Additives and Products or Substances used in 
Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the additive Roxazyme
® G2 when used as a 
zootechnical additive in poultry and piglets (weaned). The additive Roxazyme
® G2 is a preparation of endo-1,4-
beta-xylanase, endo-1,4-beta-glucanase and endo-1,(3)4-beta-glucanase produced by  a strain of Trichoderma 
reesei. The FEEDAP Panel concludes that the additive is safe for poultry species and for piglets at the maximum 
proposed dose. The results of two in vitro genotoxicity studies and a sub-chronic oral toxicity study did not 
indicate any concern for consumer safety arising from the use of the product as a feed additive. The enzymes 
contained in Roxazyme
® G2 are non-irritant to the eyes and skin and are not dermal sensitisers. The additive 
should be considered as a potential respiratory sensitiser. The active substances of Roxazyme
® G2 are proteins, 
and as such will be degraded/inactivated during the passage through the digestive tract of animals. Therefore, no 
further environmental risk assessment is required. The FEEDAP Panel concludes that Roxazyme
® G2, in either 
form, has the potential to be efficacious in the target species. The nominal dosages showing efficacy were 50 mg 
additive/kg  feed  in  chickens  for  fattening  and  ducks,  80 mg  additive/kg  feed  in  laying  hens  and  100 mg 
additive/kg feed in turkeys for fattening and piglets. The conclusions are extended to chickens reared for laying 
and turkeys reared for breeding at the corresponding dose and can be extrapolated to include all minor poultry 
species  (dose  of  50 mg/kg  for  growing  birds  and  of  80 mg/kg  for  laying  birds).  However,  based  on  the 
incomplete information provided by the applicant the FEEDAP Panel is not in a position to specify the minimum 
enzyme activities (three enzymes) that are efficacious. 
© European Food Safety Authority, 2012 
                                                       
1  On request from the European Commission, Question No EFSA-Q-2007-185, adopted on 17 October 2012. 
2  Panel members: Gabriele Aquilina, Alex Bach, Vasileios Bampidis, Maria De Lourdes Bastos, Gerhard Flachowsky, Josep 
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Mayo, Derek Renshaw, Guido Rychen, Maria Saarela, Kristen Sejrsen, Patrick Van Beelen, Robert John Wallace and 
Johannes Westendorf. Two members of the Panel did not participate in the discussion on the subject referred to above 
because  of  potential  conflicts  of  interest  identified  in  accordance  with  the  EFSA  policy  on  declarations  of  interests. 
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4  Revision  1: This scientific opinion has been edited following the adoption of the decision of the Commission on 
confidentiality claims submitted by the applicant, in accorda nce with Article 8(6) and Article 18 of Regulation (EC) No 
1831/2003. The modified sections are indicated in the text. 
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SUMMARY 
Following  a  request  from  the  European  Commission,  the  Panel  on  Additives  and  Products  or 
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the additive 
Roxazyme
® G2 when used as a zootechnical additive in poultry and piglets (weaned). The additive 
Roxazyme
® G2 is a preparation of endo-1,4-beta-xylanase, endo-1,4-beta-glucanase and endo-1,(3)4-
beta-glucanase produced by a strain of Trichoderma reesei. The applicant requests the re-evaluation of 
the product to be used in chickens for fattening, turkeys for fattening, laying hens, ducks and piglets 
and for an extension of use to all poultry.  
The additive is presented in solid (Roxazyme
® G2 G) and liquid forms (Roxazyme
® G2 L). The two 
formulations of the product are considered to be equivalent in terms of safety for the target species and 
efficacy. 
On the basis of the results obtained in tolerance studies in which a dose at least 10-fold the maximum 
dose was tested, the FEEDAP Panel concludes that the additive is safe for chickens and turkeys for 
fattening, laying hens, ducks and for piglets at the maximum proposed dose. The conclusions reached 
in  chickens  and  turkeys  for  fattening  can  be  extended  to  chickens  and  turkeys  reared  for 
laying/breeding. Since the mode of action of the enzymes contained in the additive can be reasonably 
assumed to be the same in all poultry species, the conclusions on the tolerance for major species can 
be extrapolated to include all minor poultry species (fattening and laying). 
The results of two in vitro genotoxicity studies and a sub-chronic oral toxicity study did not indicate 
any concern for consumer safety arising from the use of Roxazyme
® G2 as a feed additive. 
The enzymes contained in the additive Roxazyme
® G2 are non-irritant to the eyes and skin and are not 
dermal sensitisers. Owing to the proteinaceous nature of the active substances present in the additive, 
it should be considered a potential respiratory sensitiser.  
The active substances of Roxazyme
® G2 are proteins, and as such will be degraded/inactivated during 
the passage through the digestive tract of animals. Therefore, no further environmental risk assessment 
is required.  
Based on the results obtained in the efficacy trials conducted in the different target species, the Panel 
concludes that Roxazyme
® G2, in either form, has the potential to be efficacious in these species. The 
nominal dosages showing efficacy were 50 mg additive/kg feed in chickens for fattening and ducks, 
80 mg additive/kg feed in laying hens and 100 mg additive/kg feed in turkeys for fattening and piglets. 
The conclusions are extended to chickens reared for laying and turkeys reared for breeding at the 
corresponding  dose.  Since  the  mode  of  action  of  the  enzymes  contained  in  the  additive  can  be 
reasonably assumed to be the same in all poultry species, the conclusions on the efficacy for major 
species can be extrapolated to include all minor poultry species (dose of 50 mg/kg for growing birds 
and  of  80 mg/kg  for  laying  birds).  However,  based  on  the  incomplete  information  that  has  been 
provided by the applicant on the enzyme recoveries in the experimental feeds, the FEEDAP Panel is 
not in a position to specify the minimum enzyme activities (three enzymes) that are efficacious. Roxazyme
® G2 for poultry and piglets 
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BACKGROUND 
Regulation  (EC)  No  1831/2003
5  establishes the rules governing the Community authorisation of 
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lies down that any 
person seeking an authorisation for a feed additive or for a new use of a feed additive shall submit an 
application in accordance with Article 7.   Article 10(2) of that Regulation also sp ecifies that for 
existing products within the meaning of Article 10(1), an application shall be submitted in accordance 
with Article 7, at the latest one year before the expiry date of the authorisation given pursuant to 
Directive 70/524/EEC for additives  with a limited authorisation period, and within a maximum of 
seven years after the entry into force of this Regulation for additives authorised without time limit or 
pursuant to Directive 82/471/EEC.  
The European Commission received a request from the com pany DSM Nutritional Products Ltd
6 for 
authorisation of the product Roxazyme
® G2 (endo-1,4-beta-xylanase, endo-1,(3)4-beta-glucanase and 
endo-1,4-beta-glucanase) to be used as a feed additive for poultry and piglets (category: zootechnical 
additive; functional group: digestibility enhancers) under the conditions mentioned in Table 1.  
According  to  Article  7(1)  of  Regulation  (EC)  No  1831/2003,  the  Commission  forwarded  the 
application to the European Food Safety Authority (EFSA) as an application under Article 10(2) (re-
evaluation of an authorised additive) and as an application under Article 4(1) (authorisation of a feed 
additive  or  new use  of a feed  additive).  EFSA received  directly  from  the  applicant  the technical 
dossier in support of this application. According to Article 8 of that Regulation, EFSA, after verifying 
the particulars and documents submitted by the applicant, shall undertake an assessment in order to 
determine  whether  the  feed  additive  complies  with  the  conditions  laid  down  in  Article  5.  The 
particulars  and  documents  in  support  of  the  application  were  considered  valid  by  EFSA  as  of  2 
October 2008. 
The additive Roxazyme
® G2 is a preparation of endo-1,4-beta-xylanase, endo-1,(3)4-beta-glucanase 
and  endo-1,4-beta-glucanase  produced  by  a  strain  of  Trichoderma  reesei  (ATCC  74444).
7  This 
product is authorised for use in chickens for fattening,
8 turkeys for fattening,
9 laying hens and piglets
10 
and ducks.
11 
The Scientific Committee on Animal Nutrition issued an opinion the safety of  Roxazyme
® G2 for 
chickens and turkeys for fattening which also considered the safety for the consumer, the user and the 
environment (EC, 1998, updated 16 October 2002), and another opinion on the safety of this enzyme 
preparation  for  laying  hens  and  piglets  (EC,  2002).  EFSA  issued  an  opinion  on  the  safety  of 
Roxazyme
® G2 for ducks (EFSA, 2005). 
TERMS OF REFERENCE 
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed 
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the 
efficacy and the safety for the target animals, consumer, user and the environment of the product 
                                                       
5  Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use 
in animal nutrition. OJ L 268, 18.10.2003, p. 29. 
6  DSM Nutritional Products, represented in the EU by DSM Nutritional Products Sp.  z.o.o., Tarczynska 113, 96 -320 
Mszczonow, Poland. 
7  Formerly classified as Trichoderma longibrachiatum and deposited with the accession number ATCC 74252. 
8  Commission Regulation (EC) No 1259/2004 of 8 July 2004 concerning the permanent authorisation of certain additives 
already authorised in feedingstuffs. OJ L 239, 9.7.2004, p. 8.
 
9  Commission Regulation (EC) No 1206/2005 of 27 July 2005 concerning the permanent authorisation of certain additives in 
feedingstuffs. OJ L 197, 28.7.2005, p. 12. 
10   Commission Regulation (EC) No 1876/2006 of 18 December 2006 concerning the provisional and permanent authorisation 
of certain additives in feedingstuffs. OJ L 360, 19.12.2006, p. 126. 
11   Commission Regulation (EC) No 1811/2005 of 4 November 2005 concerning the provisional and permanent authorisations 
of certain additives in feedingstuffs and the provisional authorisation of a new use of an additive  already authorised in 
feedingstuffs. OJ L 291, 5.11.2005, p. 12. Roxazyme
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Roxazyme
® G2, which is a preparation of endo-1,4-beta-xylanase, endo-1,4-beta-glucanase and endo-
1,(3)4-beta-glucanase  produced  by  the  Trichoderma  reesei  (ATCC  74444)  when  used  under  the 
conditions described in Table 1. Roxazyme
® G2 for poultry and piglets 
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Table 1:   Description and conditions of use of the additive as proposed by the applicant  
Additive   ROXAZYME
® G2; preparation of cellulase, betaglucanase and xylanase 
Registration number/EC No/No 
(if appropriate) 
E 1602; Enzyme No 11 
Category of additive  Zootechnical additive 
Functional group of additive  Digestibility enhancer 
 
Description 
Composition, description  Chemical 
formula 
Purity criteria 
(if appropriate) 
Method of analysis 
(if appropriate) 
Endo-1,4-beta-xylanase (EC 3.2.1.8); 
Endo-1,3(4)-beta-glucanase  (EC 
3.2.1.6);  Endo-1,4-betaglucanase 
(EC  3.2.1.4)  produced  by 
Trichoderma reesei 
Solid form – ROXAZYME
® G2 G 
Liquid form - ROXAZYME
® G2 L 
 
Xylanase min. 2700 
U/g 
Betaglucanase min. 
700 U/g 
Cellulase min. 800 U/g 
 
 
Trade name (if appropriate)  Roxazyme
® G2 
Name of the holder of 
authorisation (if appropriate) 
 
DSM Nutritional Products Ltd. 
 
 
Conditions of use 
Species or 
category of animal 
Maximum 
Age 
Minimum content  Maximum content  Withdrawal 
period 
(if appropriate)  U kg
-1 of complete feedingstuffs 
Poultry 
Piglets  - 
Xylanase: 135 
Glucanase: 35 
Cellulase: 40 
   
 
Other provisions and additional requirements for the labelling 
Specific conditions or restrictions 
for use (if appropriate) 
For use in compound feed rich in non-starch polysaccharides 
Recommended dose per kg of complete feedingstuff:  
Poultry  and  piglets:  Xylanase  135  -  540  U;  Betaglucanase  35  - 
140U; Cellulase 40 - 160 U 
Specific conditions or restrictions 
for handling (if appropriate) 
Product  shall  be  labelled  as  harmful,  may  cause  sensitisation  by 
inhalation 
Post market monitoring  
(if appropriate) 
No additional requirements further to the need for traceability and 
recall procedures established by Regulation No 178/2002 
Specific conditions for use in 
complementary feedingstuffs  
(if appropriate) 
 
 
Maximum Residue Limit (MRL) (if appropriate) 
Marker residue  Species or category of 
animal 
Target tissue(s) or 
food products 
Maximum content in 
tissues 
       Roxazyme
® G2 for poultry and piglets 
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ASSESSMENT 
1.  Introduction  
Roxazyme
® G2 is a feed additive that contains three enzymes – endo-1,4-beta-xylanase (xylanase; EC 
3.2.1.8), endo-1,4-beta-glucanase (cellulase; EC 3.2.1.4) and endo-1,3(4)-beta-glucanase (glucanase; 
EC 3.2.1.6) – produced by a strain of Trichoderma reesei with the accession number ATCC 74444.
12 
This product is already authorised for use in chickens for fattening, turkeys for fattening, laying hens , 
ducks and piglets. The applicant requests the re-evaluation of the product for those species and the 
extension of its use to all poultry as a zootechnical additive under the functional group of digestibility 
enhancers.  
2.  Characterisation  
2.1.  Characterisation of the product
13  
The additive is presented in granular (Roxazyme
® G2 G) and liquid (Roxazyme
® G2 L) forms. The 
enzymatic activities of the three enzymes are expressed in units (U), and one U is the amount of 
enzyme (xylanase, cellulase or glucanase) that releases 1 µmol of reducing sugar (xylose or glucose 
equivalent) per minute at 40 °C, pH 5, from wheat arabinoxylan, carboxymethylcellulose or barley 
beta-glucan, respectively. The two forms of the additive guarantee a minimum enzyme activity of 
2 700 U xylanase/g, 800 U cellulase/g and 700 U glucanase/g product. 
Roxazyme
® G2 G is a granular, beige, odourless powder that consists of enzyme concentrate (5.0–
10.0 %), soya oil (5.3 %) and wheat flour and semolina as carriers (43.5 % each).
14 Roxazyme
® G2 G 
has a bulk density of 0.61 g/cm
3. Particle size distribution shows that ≥ 97 % of the particles are in the 
range of 250–850 µm and no particles below 250 µm are found. The formulation has a negligible 
dusting potential as measured by the Stauber–Heubach method (0 g/25 g).
15 The study of the batch-to 
batch-variation in terms of enzyme activity was provided for seven batches.
16 
Roxazyme
® G2 L is a brownish, liquid, water-miscible product that consists of enzyme concentrate 
(8.8–10.8 %), sorbitol (38–42 %), caramel colour (≤ 0.6 %, the type of caramel colour used is not 
specified), potassium sorbate (0.13–0.17 %) and water (46–53 %). Roxazyme
® G2 L shows a density 
in the range of 1.0–1.2 g/mL and a viscosity in the range of 10–20 cP. The pH is within the range 4.4– 
4.5.
17 The study of the batch -to-batch variation  in terms of  enzyme activity  was provided for  six 
batches.
18 
Regarding the purity  of the product, the data provided showed compliance of the additive with the 
specifications set by JECFA (JECFA, 2001)  for contaminats (chemical and microbiological) and the 
absence of antibiotic activity.
19,20 The presence of toxins, including aflatoxins, T-2 toxin, HT-2 toxin, 
ochratoxin A, sterigmatocystin and zearalenone, was investigated in the additive. Of the toxins studied 
only ochratoxin A could be quantified in the solid formulation, however, the values were far below the 
EU guidance levels for this mycotoxin in feed materials. For the other toxins investigated the content 
was below the limits of detection or below the limits of quantification.
21 
                                                       
12   Formerly classified as Trichoderma longibrachiatum and deposited with the accession number ATCC 74252. 
13   This section has been edited following the provisions of Article 8(6) and Article 18 of Regulation (EC) No 1831/2003. 
14   Technical dossier/Supplementary information February 2011. 
15   Technical dossier/Section II/Annex 2.31. 
16   Technical dossier/Supplementary information July 2012/Annex 1. 
17   Technical dossier/Section II. 
18   Technical dossier/Supplementary information July 2012/Annex 1. 
19   Technical dossier/Section II/Annex 2.26. 
20   Technical dossier/Supplementary information July 2012/Annex 1. 
21   Technical dossier/Supplementary information July 2012/Annex 1. Roxazyme
® G2 for poultry and piglets 
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2.2.  Manufacturing process 
The enzymes contained in the product are produced by submerged pure culture fermentation of a non-
genetically  modified  strain  of  Trichoderma  reesei. The  authorisation  was  previously  given  to  the 
product produced by a strain of Trichoderma longibrachiatum deposited at the American Type Culture 
Collection with the accession number ATCC 74252. According to the applicant, the same strain was 
deposited at the American Type Culture Collection with the accession number 74444 in 1998 (validity 
30 years).
22 The applicant provided, upon request, a full set of data to identify the strain with the 
deposition number ATCC 74444 and to establish its genetic stability.
23 The results showed that the 
strain has to be classified as  Trichoderma reesei. The applicant was also invited to demonstrate, by 
providing evidence, that the two strains deposited are the same. The company owner of the production 
strain provided only a notarised statement saying that the two strains are the same.
24 
2.3.  Stability and homogeneity
25  
Three batches of Roxazyme
®  G2 G kept in original two-layer paper/polyethylene bag material at 
25 °C showed, after 18 months, average residual activities of 85 % xylanase, 86 % cellulase and 88 % 
glucanase.  The  same  samples  were  stored  for  six  months  at  35 °C  and  showed  average  residual 
activities of these enzymes > 95 %.
26  
In two studies, seven batches of Roxazyme
® G2 L were studied for up to 24 months (one batch only 
up to 12 months and three to 18 months) when kept at 25 °C in closed bottles. Residual activities 
ranged from 92 to 99 % for xylanase, from 87 to 110 % cellulase and from 100 to 114 % glucanase.
27 
The stability of this formulation at 30 and 35 °C was studied in one and three lots and for two and six 
months, respectively. Recoveries were in all cases > 90 %. 
The stability of three lots of Roxazyme
® G2 G in three types of premixtures for chicken for fattening 
feed  was  tested:  vitamin  premixture,  without  and  with  choline  chloride,  and  complete  premix 
(including choline chloride and trace elements). After three months’ storage at 25 °C, mean recovery 
values were > 80 % in all cases.
28 
The stability of the Roxazyme
® G2 G (three batches) when added at 100 mg/kg to feedingstuffs was 
tested in feed for chickens for fattening based on maize and soybean meal.
29 From each batch, a mash 
feed and two pelleted feeds (pelleting temperature 75 °C or 80 °C) were manufactured and stored for 
three months. Recoveries after pelleting were higher than 7 2 % in all cases  with the exception of 
xylanase and glucanase, recovery of which in feed pelleted at 80 °C was 59 and 62 %, respectively. 
Storage for three months did not modify   substantially  the  post-pelleting enzyme activities.   The 
stability of the  Roxazyme
® G2 L was studied when sprayed onto pelleted feed at 100 mg/kg. Two 
diets were used (chickens for fattening and pig diets) and samples were kept for three months at 25 °C. 
Recoveries were 93 %, 88 % and 85 % of initial the activity for xylanase, cellulase and glucanase, 
respectively.  
The capacity of the additive to homogenously distribute when added to feed was studied in the above-
mentioned feed samples and was found to be within acceptable values. 
2.4.  Conditions of use  
Roxazyme
® G2 is intended for use as a feed additive in feed for poultry and for weaned piglets at a 
minimum recommended dose of 135 U xylanase, 40 U cellulase and 35 U glucanase per kg complete 
                                                       
22   Technical dossier/Supplementary information July 2012/Annex 5. 
23   Technical dossier/Supplementary information July 2012/Annex 1B to 9B. 
24   Technical dossier/Supplementary information October 2012. 
25   This section has been edited following the provisions of Article 8(6) and Article 18 of Regulation (EC) No 1831/2003. 
26   Technical dossier/Supplementary information February 2011/Annex 1 and Supplementary information July 2012/Annex 3. 
27   Technical dossier/Supplementary information July 2012/Annex 4. 
28   Technical dossier/Section II/Annex 2.31. 
29   Technical dossier/Supplementary information July2012/Annex 7. Roxazyme
® G2 for poultry and piglets 
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feed (delivered by 50 mg additive/kg feed). The maximum recommended dose is 540 U xylanase, 
160 U cellulase and 140 U glucanase per kg of complete feed (delivered by 200 mg additive/kg feed).  
2.5.  Evaluation of the analytical methods by the European Union Reference Laboratory 
(EURL) 
EFSA has verified the EURL report as it relates to the methods used for the control of the active 
substances in animal feed. The Executive Summary of the EURL report can be found in the Appendix. 
3.  Safety  
3.1.  Safety for the target species  
In  all  tolerance  studies,  enzyme  recoveries  were  reported  as  mg  additive/kg  feed.  In  the  case  of 
chickens and turkeys for fattening and laying hens, the enzyme activity in feed was measured for only 
one enzyme (in the chickens study the enzyme measured was not specified; in turkeys and laying hens 
glucanase was measured) while in piglets the enzyme/s measured was not specified. The applicant was 
requested to provide the analysed activities for the three enzymes in the experimental feeds but failed 
to do so. Instead, the applicant calculated the enzyme activities in the experimental feed based on the 
enzyme activities measured in the batches used in a given study (except in piglets). Owing to the 
overdosing of the enzymes in the batches, the calculated dosages in feed showed higher values than 
those that would result from the use of a batch compliant with the specifications of the additive.  
3.1.1.  Tolerance for chickens for fattening 
In a combined tolerance and efficacy study, a total of 2 400 one-day-old male chickens for fattening 
(Ross  308)  were  distributed  in  groups  of  50  birds  to  six  dietary  treatments  (eight  replicates  per 
group).
30 The basal diets (starter and grower) based on barley and soya bean meal were supplemented 
with Roxazyme
® G2 at 0 (control), 50, 100, 150, 200 (1 ) or 2 000 (10 ) mg/kg feed. The study lasted 
35 days and performance of the birds was measured. At the end of the study, blood samples were 
collected from two birds per pen (16 birds per treatment) and analysed for haematological parameters 
(haematocrit, haemoglobin, erythrocyte count, mean corpuscular volume (MCV), mean corpuscular 
haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC)) and for biochemical 
parameters (aspartate aminotransferase (AST), alanine aminotransferase (ALT), total serum protein 
and albumin). Following this, the animals were slaughtered for post-mortem examination.  
Mortality was low (~ 2 %) and not different between the experimental treatments. No adverse effects 
on the performance of the birds (Table 2), blood parameters or gross pathology (including weight of 
the liver and viscera) due to an overdose of Roxazyme
® G2 were observed.  
3.1.2.  Tolerance for turkeys for fattening 
In a combined tolerance and efficacy study, a total of 1 248 one-day-old turkeys (BUT-9, female 
birds) were distributed in groups of 26 birds to four dietary treatments (12 replicates per group).
31 The 
basal diets (starter, grower and finisher) based on barley and soybean meal were supplemented with 
Roxazyme
® G2 at 0 (control), 100, 200 (1 ) and 2000 (10 ) mg/kg complete feed. The study lasted 84 
days and performance of the birds was measured. At the end of the experiment, blood was collected 
from one bird per pen (12 birds per group) to measure haematological (erythrocyte count, haematocrit, 
haemoglobin,  MCV,  MCH,  MCHC)  and  biochemical  parameters  (glucose,  serum  alkaline 
phosphatase,  AST,  ALT  gamma-glutamyltranspeptidase  (GGT),  uric  acid,  albumin,  total  proteins, 
calcium and phosphorus).  
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Mortality  was  low  (~ 1 %)  and  not  different  between  treatments.  No  adverse  effects  on  the 
performance of the birds (Table 3) and on blood parameters due to an overdose of Roxazyme
® G2 
were observed. 
3.1.3.  Tolerance for laying hens 
A total of 180 laying hens (ISA Brown, 32 weeks old) kept individually were allocated to three dietary 
treatments (six replicates of 10 cages per group).
32 A wheat, maize and soybean meal diet in mash 
form was supplemented with granular  Roxazyme
® G2 at 0 (control), 200 (1 ) and 20 000 (100 ) 
mg/kg complete feed. The study lasted 56 days. The body weight, laying rate, egg weight and feed 
consumption were measured and feed to egg mass ratio was calculated.  
No animals died or were culled during the experiment. Laying rate in the 100  group (95.7 %) was 
significantly lower than in the 1  group (97.4 %) but not different from that in the control group 
(96.5 %). No differences were found in egg weight (57.4, 57.8 and 57.3 g for the control, 1  and 100 , 
respectively) or in the feed to egg mass ratio (1.97, 1.96 and 1.95, respectively). 
3.1.4.  Tolerance for ducks and other minor poultry species 
The safety of the additive in chickens and turkeys for fattening and in laying hens has been established 
in tolerance trials in which a dose at least 10-fold the maximum dose was tested. Therefore, the safety 
can be extrapolated to ducks and all other minor avian species provided that the same dose applies. 
The  safety  of  the  product  in  ducks  was  further  confirmed  in  a  tolerance  study  evaluated  by  the 
FEEDAP Panel in 2005 (EFSA, 2005).  
3.1.5.  Tolerance for piglets 
The  applicant  provided  a  tolerance  study  in  piglets  that  was  evaluated  in  2002  by  the  Scientific 
Committee on Animal Nutrition (EC, 2002). A total of 96 weaned piglets (Landrace   Pietrain, 48 
males/48 females) with an average body weight at weaning of 7.2 ± 1 kg were penned in pens of two 
pigs and allocated to one of four dietary treatments (12 replicates per treatment).
33 A barley-based diet 
was supplemented with Roxazyme
® G2 G at 0, 100, 1 000 or 10 000 (50 ) mg/kg. The diets were 
offered for 35 days. The performance of the animals was measured throughout the experimental period 
and at the end of the experiment a total of 24 piglets (six per dose group) were slaughtered to collect 
blood and to perform a necropsy including weighing various organs (liver, heart, kidney and spleen). 
Blood  samples  were  subject  to  haematological  (white  and  red  blood  cell  count,  haemoglobin 
concentration,  haematocrit,  thrombocyte  count,  differential  lymphocyte  count)  and  biochemical 
analyses (serum protein, alkaline phosphatase, ALT, AST, GGT, urea, creatinine, glucose and others).  
One animal from the control group died in the course of the experiment. No differences were found 
between groups in weight gain (~ 310 g/day) and feed to gain ratio (~ 1.76). The findings of post-
mortem  anatomical  examinations  (including  heart,  kidney,  spleen  and  liver  weight)  and 
haematological and biochemical and blood parameters revealed no differences between the treatments. 
3.1.6.  Conclusions on the tolerance for the target species 
On the basis of the results obtained from the tolerance studies performed in chickens and turkeys for 
fattening, laying hens, ducks and piglets, the FEEDAP Panel concludes that the additive is safe for 
these poultry species/categories and in piglets. The conclusions reached on the tolerance trials in 
chickens and turkeys for fattening can be extended to chickens and turkeys reared for laying/breeding.  
Since the mode of action of the enzymes contained in the additive can be reasonably assumed to be the 
same in all poultry species, the conclusions on the tolerance for major species can be extrapolated to 
include all minor poultry species (fattening and laying). 
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3.2.  Safety for the consumer 
The  test  item  used  in  the  studies  presented  below  was  the  stabilised  concentrate  (referred  to  as 
Roxazyme
® G2 in the text below) used to manufacture the product.
34 
3.2.1.  Genotoxicity studies including mutagenicity 
The mutagenicity of Roxazyme
® G2 was evaluated with the Ames test, in the presence or absence of 
an exogenous metabolic activation system (S9 from the livers of phenobarbital–betanaphthoflavone-
treated rats), in five Salmonella Typhimurium strains (TA1535, TA97, TA98, TA100 and TA102).
35 
The dose range of Roxazyme
® G2 used was 50–5 000 µg/plate. No increase in the number of revertant 
colonies was apparent in any of the five test strains while positive controls performed as expected. 
The clastogenic potential of Roxazyme
® G2 was tested in Chinese hamster V79 cells in the absence 
(three and 18 hours’ treatments) and in the presence (three and five hours’ treatments) of metabolic 
activation (S9 from the livers of phenobarbital–betanaphthoflavone-treated rats) up to a concentration 
of 5 000 µg/mL.
36 After exposure to the test article, the frequency of cells with structural chromosome 
aberrations  was  not  increased  to  a  biologically  relevant  extent.  No  induction  of  polyploidy  was 
reported.  The  sensitivity  of  the  test  system  and  the  activity  of  the  metabolic  activation  were 
demonstrated by using appropriate positive controls. 
3.2.2.  Sub-chronic oral toxicity study 
A sub-chronic oral toxicity study was performed with Wistar rats (males and females).
37 Four groups 
of 20 males and 20 females were fed to receive 0, 200, 600  or 2 000 mg Roxazyme
® G2/kg body 
weight per day. The rats received the diets for 13 weeks. At the end of this time, six rats per sex and 
per group were submitted to a withdrawal period of four weeks; the other rats were sacrificed. During 
the  study,  general  parameters  were  recorded,  and  ophthalmoscopy  and  blood  (red  blood  cells, 
haemoglobin, haematocrit, MCV, MCH, MCHC, white blood cell count (including a differential count 
in  the  control  and  highest  dose  groups),  reticulocytes,  normoblasts,  platelets,  fibrinogen, 
thromboplastin  time,  AST,  ALT,  alkaline  phosphatase,  GGT,  total  bilirubin,  urea,  glucose, 
triglycerides,  total  cholesterol,  total  protein,  serum  proteins  and  electrolytes)  and  urine  analyses 
(specific gravity, pH, protein, glucose, ketones, bilirubin, blood, nitrite, urobilinogen, urinary sediment 
in the control and highest dose groups) were carried out. Post-mortem examinations were carried out 
and histopathological examination of several tissues was performed in animals in the control and high-
dose groups. Two male rats died during the study, but the deaths were not related to treatment. There 
was no effect of treatment on clinical observations, body weight or feed intake. Various differences 
were seen between treated and control groups in haematological values; however, these were small 
and not consistently present,  and thus are not considered to be due to treatment. Serum analyses 
showed that many  values in the high- and intermediate-dose groups were different from those in 
controls; however, most differences were not present in both sexes and values remained within the 
tolerable physiological ranges. Slightly elevated serum GGT levels were seen consistently in both 
sexes on all occasions in the highest two dose groups, including after the reversal period. Relative liver 
weight was increased in males at the end of the study in both the highest and the intermediate-dose 
groups. Among females, relative kidney weight was increased in the same groups. There were no 
treatment-related findings at necropsy or  on histopathological examination. Although some of the 
differences  seen  may  be  related  to  treatments,  there  are  no  adverse  effects  of  relevance  to  risk 
assessment for consumers of products from Roxazyme
® G2-fed animals. 
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3.2.3.  Conclusions on the safety for the consumer 
The results of two in vitro genotoxicity tests and a sub-chronic oral toxicity study did not indicate any 
concern  for  consumer  safety  arising  from  the  use  of  Roxazyme
®  G2  as  a  feed  additive  in  food-
producing species. 
3.3.  Safety for the user 
The  test  item  used  in  the  studies  presented  below  was  the  stabilised  concentrate  (referred  to  as 
Roxazyme
® G2 in the text below) used to manufacture the product.
38 
3.3.1.  Irritancy tests 
An eye
39 and a skin
40 irritation study were provided by the applicant. The studies were conducted 
separately and both studies were carried out in three young adult New Zealand White rabbits. The eye 
irritation study was carried out by instillation of 0.1 g of the product Roxazyme
® G2 (crystalline) into 
the conjunctival sac of the left eye of the animals. Treated eyes were not rinsed after the application of 
the substance. Corneal, iridic and conjuctival irritation was evaluated at 1, 24, 48 and 72 hours after 
the administration of the test article. The application of the tested product caused slight eye irritation 
in one animal, which persisted for 24 hours and was resolved completely by 48 hours.  
For the skin irritation test, Roxazyme
® G2 moistened with double-distilled water was applied to the 
skin for four hours under a semi-occlusive dressing. Skin reactions were recorded 1, 24, 48 and 72 
hours after removal of the test item. Slight erythema was found in one of the animals after 1 and 24 
hours, which was completely resolved by 48 hours. 
Based on the results obtained, the product is classified as non-irritant to either the eye or skin. 
3.3.2.  Skin sensitisation 
Dermal sensitisation potential was assessed in a guinea pig maximisation test
41 according to OECD 
guideline 406 with 20 test and  10 control animals. No reactions were observed; thus, this product is 
not considered to be a dermal sensitiser under the conditions of the test. 
Both photoallergenic
42 and cutaneous phototoxic potential
43 were investigated in specifically designed 
trials using guinea pigs, both showing negative results.  
3.3.3.  Effects on the respiratory system 
A  study  investigated  the  effect  of  Roxazyme
®  G2  on  the  respiratory  rate  of  mice  in  a  short 
exposure/observation protocol.
44 Three groups were used: control, one group exposed to the product 
for 3.6 minutes at a chamber concentration of 330  µg/L and the third group exposed to the same 
concentration for 5 minutes. Respiratory rate was measured up to 15 minutes after  the exposure. All 
the animals exhibited a slight reduction in the mean respiratory rate, but no differences were found 
between the control and product-exposed animals. Under the test conditions used, it is concluded that 
Roxazyme
®  G2  has  no  irritating  effects  on  the  upper  respiratory  system  during  a  short  exposure 
period.  
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3.3.4.  Conclusions on user safety 
The enzymes contained in the additive Roxazyme
® G2 are non-irritant to the eyes and skin, and are 
not dermal sensitisers. Owing to the proteinaceous nature of the additive, it should be considered a 
potential respiratory sensitiser.  
3.4.  Safety for the environment 
The active substances of Roxazyme
® G2 are proteins, and as such will be degraded/inactivated during 
the passage through the digestive tract of animals. Therefore, no further environmental risk assessment 
is required.  
4.  Efficacy  
The additive is an enzyme preparation that contains three enzymes. The recoveries in feed of only one 
or  two  enzymes  were  measured  and  were  reported  as  mg  additive/kg  feed.  The  applicant  was 
requested to provide the analysed activities for the three enzymes in the experimental feeds. In the 
absence of this information, however, the enzyme activities in the experimental feed were calculated 
by the applicant based on the enzyme activities measured in the batches used for a given trial or on 
historical batch data.  
In the text below the intended values of enzyme supplementation in feed are given as mg additive/kg 
feed. For the determination of the effective dose, a figure for enzyme units is provided. However, 
these figures are the result of calculations. Calculated enzyme activities in the experimental feeds 
showed xylanase activity similar to the values that would result from the use of a batch showing the 
minimum specifications, whereas values for cellulase were 1.6 and for glucanase 2.2 times higher. 
These calculations reflected the overdose found in the batches used.  
4.1.  Efficacy in chickens for fattening  
Four performance trials were provided. The design and main results of the overall experimental period 
are summarised in Table 2. 
The trials were carried out using chickens of the Ross strain and, with the exception of trial 3, only 
males were used. The first two trials followed a dose–response design. The first trial is the combined 
tolerance/efficacy trial (see section 3.1.1); in the second trial, the dietary treatments were obtained by 
supplementing a wheat-based diet with Roxazyme
® G2 L at 0, 50, 100 or 200 mg/kg feed. The third 
trial was carried out following a 2   2   2 factorial design. The factors considered were the main 
cereal included in the basal diet (wheat vs. barley), the sex of the animals (male vs. female) and the 
addition of Roxazyme
® G2 G (0 vs. 100 mg/kg). In the fourth trial, a basal diet based on barley was 
supplemented with Roxazyme
® G2 G at 0 or 50 mg/kg feed. In all four trials, the feed was presented 
as pellets. The duration of the studies was at least 35 days and performance of the birds was measured. 
Mortality was not affected by the dietary treatments. Supplementation with Roxazyme
® G2 at a dose 
of  50 mg/kg
  resulted  in  a  significantly  higher  body  weight  gain  and  improved  feed  to  gain  ratio 
compared with the unsupplemented diet (trials 1, 2 and 4). No interactions were seen in the third trial 
and, therefore, values presented in Table 2 are the mean values for the two basal diets and both sexes. 
Supplementation with Roxazyme
® G2 at 100 mg/kg (trials 1, 2 and 3) significantly improved feed to 
gain ratio and resulted in a higher body weight gain (trials 1 and 2).  
In the three trials in which 50 mg Roxazyme
® G2 per kg
 feed was tested, it had a positive effect on the 
performance of the birds. This dose would result in 135 U xylanase, 40 U cellulase and 35 U beta-
glucanase per kg feed. The calculated enzyme activities were (mean values in the three trials): 180 U 
xylanase, 58 U cellulase and 70 U glucanase per kg feed. Roxazyme
® G2 for poultry and piglets 
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Table 2:   Effects of Roxazyme
® G2 on the performance of chickens for fattening 
Trial  
Total no of birds 
(replicates/ group 
 birds/group)  
Sex 
Duration 
(days) 
 Basal 
diet 
Roxazyme
® 
G2 (mg/kg 
feed) 
Daily 
weight 
gain
 
Feed to 
gain 
(g/g) 
Mortality 
(%) 
1
45 
2 400 
(8   50) 
♂ 
35  Barley 
0  49.0
c  1.69
a  4.7 
50  57.3
b  1.64
b  2.2 
100  58.7
a  1.62
b  2.9 
150  56.8
b  1.61
c  2.7 
200  59.7
a  1.60
c  4.9 
2000  59.4
a  1.56
d  1.7 
2
46  
2 400 
(12   50) 
♂ 
42  Wheat 
0  60.5
b  1.86
a  2.8 
50  63.1
a  1.82
b  4.5 
100  62.9
a  1.80
c  3.5 
200  63.2
a  1.77
d  2.3 
3
47 
1 920 
(12   80) 
♂/♀ 
42  Barley or 
wheat 
0  50.6  1.86
a  3.1 
100  51.4  1.81
b  2.9 
4
48 
1 200 
(12   50) 
♂ 
35  Barley  
0  58.8
b  1.66
a  2.3 
50  60.1
a  1.62
b  2.1 
a,b,c,dMeans within a column for a given trial not sharing a common superscript are significantly different (P < 0.05). 
4.2.  Efficacy in turkeys for fattening  
Three performance trials in female turkeys  were considered for the assessment of the efficacy of 
Roxazyme
® G2 in turkeys. The characteristics of the trials and the main results can be found in Table 
3. 
In the first experiment, diets based on wheat and barley were supplemented with Roxazyme
® G2 G at 
0, 50, 100, and 200 mg/kg complete feed. The second trial was conducted with a basal diet based on 
wheat and rye, which was supplemented with granular Roxazyme
® G2 at 0, 50 or 100 mg/kg complete 
feed. The third trial, a combined tolerance/efficacy trial (see section 3.1.2), was performed with a 
barley diet which was supplemented with granular Roxazyme
® G2 at 0, 100, 200 or 2 000 mg/kg 
complete  feed  (see  section  3.1.2).  In  all  the  trials,  feed  was  presented  in  pelleted  form  and  the 
minimum duration was 84 days. The parameters measured included feed intake and body weight gain. 
The feed to gain ratio was calculated. 
Mortality was within the normal range and not affected by treatment. The supplementation of the diets 
with Roxazyme
® G2 resulted in higher final body weight/weight gain in trial 3 and a better feed to 
gain ratio in trials 1, 2 and 3. Significant improvements at 50 mg/kg of Roxazyme
® G2 were found 
only for feed to gain ratio in trial 2. At 100 mg/kg Roxazyme
® G2, weight gain was significantly 
increased in trial 3 and the feed to gain ratio was improved in trials 1 and 2. 
A positive effect on the performance of the turkeys was found in three trials at the dose of 100 mg 
Roxazyme
® G2 per kg
 feed. The dose of 100 mg Roxazyme
® G2 per kg feed would result in 270 U 
xylanase, 80 U cellulase and 70 U glucanase per kg feed. The calculated enzyme activities were (mean 
values in three trials) 263 U xylanase, 102 U cellulase and 119 U glucanase per kg feed. 
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Table 3:   Effect of Roxazyme
® G2 on the performance of turkeys 
Trial  
Sex 
Total no of birds 
(replicates/group 
 
birds/replicate)* 
Trial 
duration 
(days) 
 Basal 
diet 
Roxazyme
® 
G2
†  
(mg/kg feed) 
Final body 
weight
‡  
(kg) 
Feed/ 
gain 
(kg/kg) 
Mortality 
(%)
§ 
1
49 
♀ 
1 488 
(12   31) 
(12   25) 
84  Wheat/ 
barley 
0  6.22  2.12
a  1.6 
50  6.16  2.09
b  3.1 
100  6.19  2.08
b  1.6 
200  6.17  2.07
b  1.3 
2
50 
♀ 
330 
(11    10) 
(11   8) 
112  Wheat/ 
rye 
0  10.84  2.76
a  8.0 
50  10.95  2.76
a  4.5 
100  11.03  2.67
b  4.5 
3
51 
♀ 
1 248 
(12   26) 
84  Barley 
0  6.39
b  2.29
a  0.3 
100  6.53
a  2.24
ab  0.0 
200  6.50
ab  2.19
bc  1.3 
2000  6.62
a  2.15
c  1.3 
*The number of animals per pen was reduced on week 4 in trial 1, and on week 10 in trial 2.  
†In the trials, the granular form was tested.  
‡In trial 3 total body weight gain. 
§In trial 2, values reflect the animals that died or were culled from week 10 onwards (n = 88). During the first 10 weeks in the 
sequence of the groups two animals (1.8 %), one animal (0.9 %) and no animals died. 
a, b,c
Means within a column for a given trial not sharing a common superscript are significantly different (P < 0.05).  
4.3.  Efficacy for laying hens  
Four experiments were considered for the assessment of the efficacy of Roxazyme
® G2 in laying hens; 
a summary of the characteristics and the main results are given in Table 4. 
The first and the fourth trials were dose–response trials and were performed, respectively, on 22-week-
old Hy-Line brown hens and 20-week-old Isa brown hens. In these trials, a wheat- or a wheat/barley-
based diet, respectively, was supplemented  with 0, 80 or 100 mg Roxazyme
® G2 G/kg
 feed. The 
second and third trials were carried out on 20-week-old hens (Hy-Line brown), with one level of 
supplementation (80 mg/kg complete feed). In the second trial, the diet was based on wheat, and in the 
third trial two basal diets were tested, one based on wheat and one based barley (factorial design, 
2   2). The duration of the studies was at least 26 weeks. The parameters measured during the studies 
included performance parameters, and in trials 1 and 2 quality parameters of the eggs were measured 
(data not shown). 
No hens died in trials 3 and 4; the mortality rate in the trials 1 and 2 showed no treatment-related 
effects. Supplementation with 80 mg of Roxazyme
® G2/kg complete feed significantly improved the 
feed to egg mass ratio in one trial, while laying rate and egg weight were significantly improved in one 
trial each (trial 3 and 4, respectively).  
The dose of 80 mg Roxazyme
® G2 per kg feed would result in 216 U xylanase, 64 U cellulase and 
56 U glucanase per kg feed. The calculated enzyme activities (mean values in three trials) were 268 U 
xylanase, 113 U cellulase and 138 U glucanase per kg feed. 
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Table 4:   Effect of Roxazyme
® G2 on the performance of laying hens* 
Trial 
Total no of 
animals 
(replicates/group   
birds/replicate) 
Trial 
duration 
(weeks) 
Basal 
diet 
Roxazyme
® 
G2  
(mg/kg feed) 
 
Egg 
weight 
(g) 
Laying 
rate 
(%) 
Feed/egg 
(kg/kg) 
Mortality 
(%) 
1
52 
1440 
(6    80) 
32  Wheat 
0  67.2  84.8  1.88  1.9 
80  66.9  85.1  1.87  1.1 
100  67.1  85.1  1.87  1.3 
2
53 
360 
(12   15) 
48  Wheat 
0  63.2  84.5  1.96
a  3.3 
80  63.2  85.9  1.92
b  2.2 
3
54 
288 
(18   4) 
28 
Wheat 
0  58.6
a  85.8
a  2.10
a  0 
80  59.1
a  86.6
ab  2.07
a  0 
Barley 
0   60.5
b  84.8
a  2.04
ab  0 
80  59.5
ab  89.1
b  1.99
b  0 
4
55 
180 
(6    10) 
26 
Wheat/ 
barley 
0  64.1
a  95.7  2.03  0 
80  65.6
b  96.1  1.99  0 
100  65.1
ab  95.7  2.00  0 
* Overall experimental period results with the exception of trial 1, for which the values presented are the results obtained in 
the second half of the experiment. 
a,b Means within a column for a given trial not sharing the same superscript are different (P < 0.05; P < 0.01 for trial 3). 
4.4.  Efficacy for ducks  
Three trials are reported by the applicant in order to prove the efficacy of Roxazyme
® G2 in ducks, 
details on the trials and some results of the overall period can be found in Table 5. Two of the trials, 1 
and 3, were dose-response trials that were carried out in male ducks (Muscovy and Peking ducks, 
respectively). In both trials, the product was used in its granular form and it was included at 0, 50, 100 
and 200 mg/kg in a basal diet based on wheat. The trial 2 was carried out with Mullard ducks and 
included two variation factors: cereal present in the diet (barley, triticale, or barley + triticale), and the 
presence of the enzyme (0 vs. 100 mg/kg). In all trials performance parameters were measured. In trial 
2 the results were summarised for the three types of basal diet and the means represent the groups 
without vs. with enzyme addition. 
In trial 3 supplementation with Roxazyme
® G2 at 50 mg/kg
 significantly improved feed to gain ratio, 
while an improvement on the final body weight was observed at doses of 100 and 200 mg/kg. 
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Table 5:   Effects of Roxazyme
® G2 on the performance of ducks 
Trial  
Sex 
Total no of 
animals 
(replicates/group 
   
birds/replicate) 
Trial 
duration 
(days) 
Basal diet 
Roxazyme
® 
G2*  
(mg/kg 
feed) 
Final 
weight 
(kg) 
Feed/gain 
(kg/kg) 
Mortality 
(%) 
1
56  
♂ 
1 200 
(6   55/45)† 
84  Wheat 
0  4.76  2.99  0.7 
50  4.84  2.97  0.8 
100  4.80  2.98  0.9 
200  4.81  2.99  0.8 
2
57  
♂ 
720 
(12    30) 
49 
Barley or 
triticale or 
barley + 
triticale 
0   2.92  2.51  0.0 
100  2.96  2.49  0.2 
3
58 
♂ 
3 200 
(8   100) 
49  Wheat 
0  4.16
c  2.22
a  3.0 
50  4.20
bc  2.17
b  2.8 
100  4.26
a  2.17
b  3.3 
200  4.24
ab  2.17
b  3.4 
* In the trials the granular form was tested. 
†  Three replicates of 55 animals and three of 45 animals. 
a,b,c Means in a column within a given trial not sharing a common superscript are significantly different (P < 0.05).  
4.5.  Efficacy for piglets  
Four performance trials and a digestibility study were carried out in weaned piglets in order to support 
the efficacy of Roxazyme
® G2. The main characteristics and some results of the four performance 
trials are given in Table 6; the fifth, a digestibility study in cannulated pigs, is described in the text.  
Three of the performance studies were carried out in a dose–response manner, using the granular form 
of Roxazyme
® G2, and the minimum dose tested in all the experiments was 50 mg/kg. The fourth 
study included only one dosage of the additive. Basal diets based on cereals and soybean meal were 
offered in all cases as pellets and for at least 41 days. The body weight of the animals and feed intake 
were measured throughout the experimental period and feed to gain ratio was calculated. The second 
trial also included a digestibility study in which the apparent faecal digestibility of dry matter, organic 
matter, gross energy, crude protein and crude fat were measured.  
The results showed improvements in the performance of the pigs in two trials only. In one trial (trial 
3), piglet weight gain was significantly higher in the group receiving Roxazyme
® G2 at a dose of 
50 mg/kg feed than in the control group. In two trials (trials 3 and 4), a significantly better feed to gain 
ratio  was  obtained  at  a  dose  of  100 mg/kg  feed than  in  the  control  group. No  differences in the 
digestibility of the dietary compounds in trial 2 were observed (data not shown). 
In the fifth study,
59 the effect of Roxazyme
® G2 on the ileal and whole-tract digestibility of the dietary 
constituents was studied. The trial was carried out in 11 female piglets (15 kg body weight) following 
a Latin square design, and supplementing a rye-based diet with  Roxazyme
®  G2 at 0, 50, 100  or 
200 mg/kg. Animals were fitted with simple T-cannula at the terminal ileum. The results showed that 
Roxazyme
® G2 at 100 and 200 mg/kg improved apparent ileal digestibility of dry matter (DM; 62.7 % 
vs. 66.1 % in the control and enzyme groups (mean value)), neutral detergent fibre (NDF; 57.8 % vs. 
64.7 %), total  non-starch polysaccharides  (NSP;  11.3 %  vs. 26.7 %)  and  arabinoxylans (2.6 %  vs. 
16.5 %) compared with the unsupplemented diet. Improvements in pigs fed a diet supplemented with 
200 mg/kg
 Roxazyme
® G2 compared with those fed the unsupplemented diet were also found in the 
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whole-tract apparent digestibility of DM (87.0 % vs. 88.5 %), organic matter (88.8 % vs. 90.1 %), 
NDF (81.4 vs. 83 %) and energy (85.6 % vs. 87.3 %). 
The applicant pooled the data obtained in the four performance trials to perform a further statistical 
evaluation of the data.
60 The pooling study considered only the dietary groups supplemented with 0 or 
100 mg  Roxazyme
®  G2/kg,  resulting  in  a  total  of  110  observations  evaluated  (pen  basis):  18 
observations  from  trial  1,  32  observations  from  trial  2,  24  observations  from  trial  3  and  36 
observations from trial 4. In the study, trial location was considered as a random effect and initial body 
weight was used in the model as a covariate. The parameters studied were body weight, average daily 
gain  and  feed  to  gain ratio.  Data  were  subject  to  a  homogeneity  check.  The  results  showed that 
Roxazyme
® G2 at 100 mg/kg feed, compared with the control diet, improved the average daily gain of 
piglets (451 vs. 432 g/day; P < 0.05) and the feed to gain ratio (1.54 vs. 1.62; P < 0.05). 
Table 6:   Effect of Roxazyme
® G2 on the performance of weaned piglets 
Trial 
Sex 
Total no of 
animals 
(replicates/group 
 
pigs/replicate) 
Trial 
duration 
(days) 
Initial 
body 
weight 
(kg) 
Basal 
diet 
Roxazyme
® 
G2 
(mg/kg 
feed) 
Weight 
gain 
(g/day) 
Feed 
to 
gain 
ratio 
Mortality/culling 
(no of piglets) 
1
61 
♂/♀  
72 
(9   2) 
42  5.3  Wheat/ 
rye 
0  393  1.55  0 
50  423  1.49  1 
100  401  1.49  0 
200  428  1.52  0 
2
62 
♂/♀  
48  
(16   1) 
42  8.3  Wheat/ 
barley 
0  472  1.60  0 
50  515  1.55  0 
100  505  1.58  0 
3
63 
♂/♀ 
216 
(12   6) 
42  6.4 
 
Wheat/ 
barley 
0 
50 
100 
398
b 
412
a 
431
a 
1.60
a 
1.59
ab 
1.57
b 
0 
0 
0 
4
64 
–  
108 
(18   3) 
41  8.3  Wheat  0 
100 
437 
441 
1.69
a 
1.51
b 
1 
1 
a,b
Means in a column not sharing a common superscript are significantly different (P < 0.05). 
The dose of 100 mg Roxazyme
® G2 per kg feed would result in 270 U xylanase, 80  U cellulase and 
70 U glucanase per kg feed. The calculated enzyme activities (mean values in the four performance 
trials) were 317 U xylanase, 155 U cellulase and 187 U glucanase per kg feed. 
4.6.  Conclusions on the efficacy for the target species 
Based on the results of several efficacy studies, the FEEDAP Panel concludes that Roxazyme
® G2 in 
either form has the potential to be efficacious when incorporated in feed for chickens and turkeys for 
fattening, layings hens and piglets. The nominal doses showing efficacy were 50 mg additive/kg feed 
in chickens for fattening and ducks, 80 mg additive/kg feed in laying hens and 100 mg additive/kg 
feed in turkeys for fattening and piglets.  
The conclusions are extended to chickens reared for laying and turkeys reared for breeding. Since the 
mode of action of the enzymes contained in the additive can be reasonably assumed to be the same in 
all poultry species, the conclusions on the efficacy for major species can be extrapolated to include all 
minor poultry species (dose of 50 mg/kg for fattening birds and of 80 mg/kg for laying birds). 
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However,  based  on  the  incomplete  information  on  enzyme  recoveries  in  the  experimental  feeds 
provided by the applicant, the FEEDAP Panel is not in a position to specify the minimum enzyme 
activities (three enzymes) that are efficacious. 
CONCLUSIONS  
The additive is presented in solid and liquid forms, the two formulations of the product are considered 
to be equivalent in terms of safety for the target species and efficacy. 
The FEEDAP Panel concludes that the additive is safe for chickens and turkeys for fattening, laying 
hens, ducks and piglets at the maximum proposed dose. The conclusions reached on chickens and 
turkeys for fattening can be extended to chickens and turkeys reared for laying/breeding. Since the 
mode of action of the enzymes contained in the additive can be reasonably assumed to be the same in 
all poultry species, the conclusions on the tolerance for major species can be extrapolated to include 
all minor poultry species (fattening and laying). 
The results of two in vitro genotoxicity studies and a sub-chronic oral toxicity study did not indicate 
any concern for consumer safety arising from the use of the additive as a feed additive. 
The enzymes contained in the additive Roxazyme
® G2 are non-irritant to the eyes and skin and are not 
dermal sensitisers. Owing to the proteinaceous nature of the active substances present in the additive, 
it should be considered a potential respiratory sensitiser.  
The active substances of Roxazyme
® G2 are proteins, and as such will be degraded/inactivated during 
the passage through the digestive tract of animals. Therefore, no further environmental risk assessment 
is required.  
Based  on  the  results  obtained  in  the  efficacy  trials  provided  in  the  different  target  species,  the 
FEEDAP Panel concludes that Roxazyme
® G2, in either form, has the potential to be efficacious in the 
target species. However, based on the incomplete information that has been provided by the applicant 
on the enzyme recoveries in the experimental feeds, the FEEDAP Panel is not in a position to specify 
the minimum enzyme activities (for the three enzymes) that are efficacious. 
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APPENDIX 
Executive Summary of the Evaluation Report of the Community Reference Laboratory for Feed 
Additives on the Method(s) of Analysis for Roxazyme
® G2
65 
The  current  application  authorisation  is  sought  for  Roxazyme
®  G2  G  and  L  under  the  category 
‘zootechnical additives’, group 4(a), according to the classification system of Annex I of Regulation 
(EC)  No  1831/2003.  Specifically,  authorisation  is  sought  to  use  Roxazyme
®  G2  G  and  L  as  a 
digestibility enhancer for chicken and turkey for fattening, laying hens, ducks and piglets (weaned). 
The product is intended to be marketed as solid (Roxazyme
® G2 G) and liquid (Roxazyme
® G2 L) 
formulations.  
The active agents of Roxazyme
® G2 G and L are (1) endo-1,4- -xylanase (2) endo-1,3(4)- -glucanase 
and (3) endo-1,4- -glucanase produced by Trichoderma reesei. The enzymatic activities are expressed 
in U-unit. According to the applicant one U-unit is the amount of the enzyme (endo-1,4- -xylanase or 
endo-1,3(4)- -glucanase or endo-1,4- -glucanase) which releases 1 μmol of reducing sugar (glucose 
or xylose equivalent) per minute at 40ﾰC, pH = 5.0 from the wheat arabinoxylan or barley β-glucan or 
carboxymethylcellulose, respectively. 
The solid and liquid formulations (Roxazyme
® G2 G and L) have an endo-1,4- -xylanase activity of 
2700 U/g of product, an endo-1,3(4)- -glucanase activity of 700 U/g of product and an endo-1,4- -
glucanase activity of 800 U/g of product. Both formulations are intended to be mixed into premixtures 
and/or feedingstuffs to provide in feedingstuffs a minimum endo-1,4- -xylanase activity of 135 U/kg, 
endo-1,3(4)- -glucanase activity of 35 U/kg and endo-1,4- -glucanase activity of 40 U/kg. 
For the determination of the activity of endo-1,4- -xylanase, endo-1,3(4)- -glucanase and endo-1,4- -
glucanase in the feed additives the applicant proposes a colorimetric method based on the formation of 
reducing  sugar  moieties  released  by  the  enzymes  reacting  with  dinitrosalysilic  acid  (DNS).  The 
method was ring-trial validated by four external laboratories for the feed additives.  
·  For  the  determination  of  endo-1,4-betaxylanase  activity  the  reported  performance 
characteristics were: (1) a relative standard deviation for repeatability (RSDr) ranging from 4.0 
to 5.0% and (2) a relative standard deviation (RSD) for between-laboratory reproducibility 
ranging from 5.0 to 10.0%.  
·  For  the  determination  of  endo-1,3(4)-betaglucanase  activity  the  reported  performance 
characteristics were: (1) a RSDr ranging from 3.0 to 7.0% and (2) a RSD of reproducibility 
ranging from 4.0 to 9.0%.  
·  For  the  determination  of  endo-1,4-betaglucanase  activity  the  reported  performance 
characteristics were: (1) a RSDr ranging from 4.0 to 8.0% and (2) a RSD of reproducibility 
ranging from 2.0 to 9.0% for endo-1,4-betaglucanase.  
Based on these acceptable performance characteristics, the applicant method is found suitable for 
official controls of the activities of the above mentioned three active substances in the feed additives.  
For the determination of the activity of endo-1,4- -xylanase, endo-1,3(4)- -glucanase and endo-1,4- -
glucanase  in  the  premixtures  and  feedingstuffs  the  applicant  proposed  three  in-house  validated 
colorimetric methods, based on the same analytical principle, but using different substrates compared 
to  the  assay  on  the  feed  additive:  the  measurement  of  the  rate  of  release  of  water  soluble  dyed 
fragments by the enzymes from the dye cross-linked substrates.  
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·  For  the  determination  of  endo-1,4-betaxylanase  in  the  premixtures  and  feedingstuffs  the 
reported performance characteristics were: (1) a  RSDr ranging from 10 to 15% and (2) a 
relative standard deviation for intermediate precision (RSDR) ranging from 12 to 15%. The 
applicant determined only for the feedingstuffs a recovery rate ranging from 97 to 105% and 
the  limit  of  detection  (LOD)  and  limit  of  quantification  (LOQ)  of  15-30  and  70  U/kg 
feedingstuffs, respectively.  
·  For the determination of endo-1,3(4)-betaglucanase in the premixtures and feedingstuffs the 
reported performance characteristics were: (1) a RSDr ranging from 3 to 5% and (2) a RSDR 
ranging from 1 to 4%. The applicant determined only for the feedingstuffs a recovery rate 
ranging  from  96  to  106%  and  the  LOD  and  LOQ  of  4-7  and  18  U/kg  feedingstuffs, 
respectively.  
·  For  the  determination  of  endo-1,4-betaglucanase  in  the  premixtures  and  feedingstuffs  the 
reported performance characteristics were: (1) a RSDr ranging from 3 to 16% and (3) a RSDR 
ranging from 10 to 16%. The applicant determined only for the feedingstuffs a recovery rate 
ranging  from  98  to  104%  and  the  LOD  and  LOQ  of  4-8  and  20  U/kg  feedingstuffs, 
respectively.  
The reported LOD and LOQ values were found to be below the minimum recommended activity 
levels in feedingstuffs of 135, 35 and 40 U/kg for endo-1,4-betaxylanase, endo-1,3(4)-betaglucanase 
and endo-1,4-betaglucanase, respectively. The premixture samples were validated at a target activity 
level  of  endo-1,4-betaxylanase  of around  18000  U/kg,  endo-1,3(4)-betaglucanase  of around  5500 
U/kg premixture and endo-1,4-betaglucanase of around 5000 U/kg premixture.  
Based on these acceptable performance characteristics the CRL recommends three in-house validated 
methods  for  official  controls  for the determination  of  endo-1,4-betaxylanase,  endo-1,3(4)-
betaglucanase and endo-1,4-betaglucanase activities in the feedingstuffs and premixtures in the frame 
of Authorisation. 
Further testing or validation is not considered necessary. 
 